Full-Time

VP – Early Clinical Research Physician

Confirmed live in the last 24 hours

Schrödinger

Schrödinger

501-1,000 employees

Computational platform for biopharmaceutical research

Government & Public Sector
Enterprise Software
Biotechnology

Compensation Overview

$260k - $325kAnnually

Senior

Cambridge, MA, USA + 1 more

More locations: New York, NY, USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • M.D./Ph.D. or a MD with a focus on oncology (preferably board-certified in medical oncology or hematology/oncology) with significant scientific research experience
  • Minimum of 5 years of experience in early-phase clinical development of oncology drugs, including experience leading clinical research within the pharmaceutical industry or academia is preferred
  • Strong knowledge of clinical trial design and statistical analysis
  • Experience interacting with regulatory agencies (FDA, EMA)
  • Excellent communication skills, both written and verbal
  • Ability to work collaboratively in a fast-paced, dynamic environment
Responsibilities
  • Provide medical leadership in the design and conduct early clinical Phase 1 and Proof-of-Concept development trials, assess clinical safety and efficacy data, and write clinical study reports, clinical sections of INDs, Investigator Brochures
  • Work closely with biomarker, drug safety, clinical operations translational research scientists. You will interpret reports, prepare oral and written results of product research, and participate in the discussion and prioritization of strategies formulated within the oncology and immunology disease areas
  • Work collaboratively with the cross-functional compound development team on strategic planning, study design and execution of early-phase clinical trials, including protocol development, safety monitoring, and data analysis.
  • Collaborate with translational sciences to validate potential biomarkers for patient selection and pharmacodynamic evaluation
  • Lead outreach and interactions with key opinion leaders, clinical investigators, and other key stakeholders to build relationships and ensure alignment on clinical development plans and clinical study execution
  • Provide medical oversight for clinical trials and ensure patient safety and ensure clinical trials are conducted in accordance with all relevant regulations and guidelines, including Good Clinical Practice (GCP)
  • Contribute to clinical sections of regulatory submissions and represent Schrodinger at regulatory meetings
  • Participate in the review of preclinical data and support decision-making related to drug development
  • Stay current with emerging scientific and clinical developments in oncology and translational medicine

Schrödinger provides a computational platform that aids in the research efforts of biopharmaceutical companies, academic institutions, and government laboratories around the world. Their platform offers advanced computational tools that help in drug discovery and development across various therapeutic areas. Schrödinger's products work by utilizing sophisticated algorithms and simulations to predict molecular behavior, which assists researchers in identifying potential drug candidates more efficiently. What sets Schrödinger apart from its competitors is its extensive global reach, serving clients in over 70 countries, and its dual focus on both software licensing and collaborative drug discovery programs. The company's goal is to enhance scientific research and innovation by providing powerful computational resources that accelerate the drug discovery process.

Company Stage

IPO

Total Funding

$362.7M

Headquarters

New York City, New York

Founded

1990

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • $19.5M Gates Foundation grant boosts platform use for neglected diseases, expanding market reach.
  • Collaboration with Avicenna Biosciences enhances drug discovery efficiency through machine learning.
  • Schrödinger's AI integration aligns with industry trends, potentially increasing competitive advantage.

What critics are saying

  • Recursion and Exscientia merger creates strong competition in AI-driven drug discovery.
  • Avicenna's independent expansion could lead to competitive tensions with Schrödinger.
  • Rising drug discovery costs may challenge Schrödinger's resource allocation and capabilities.

What makes Schrödinger unique

  • Schrödinger's platform supports diverse clients, including biopharmaceutical companies and academic institutions.
  • The company excels in rapid drug candidate identification, exemplified by SGR-1505 discovery.
  • Schrödinger's predictive toxicology tools enhance drug safety and reduce development failures.

Help us improve and share your feedback! Did you find this helpful?